4D pharma has leveraged growing knowledge in the field, by creating a novel class of medicines called live biotherapeutic products (LBPs). Never miss a story ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

Defining the microbiome space is 4D pharma and its pioneering live biotherapeutic products (LBPs), an emerging class of medicines based on single strains of commensal bacteria. “We understand ...

D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.